104 related articles for article (PubMed ID: 11371932)
1. Cross-resistance and combined cytotoxic effects of paclitaxel and cisplatin in bladder cancer cells.
Pu YS; Chen J; Huang CY; Guan JY; Lu SH; Hour TC
J Urol; 2001 Jun; 165(6 Pt 1):2082-5. PubMed ID: 11371932
[TBL] [Abstract][Full Text] [Related]
2. Cytotoxicity of arsenic trioxide to transitional carcinoma cells.
Pu YS; Hour TC; Chen J; Huang CY; Guan JY; Lu SH
Urology; 2002 Aug; 60(2):346-50. PubMed ID: 12137851
[TBL] [Abstract][Full Text] [Related]
3. Paclitaxel and cisplatin as intravesical agents against non-muscle-invasive bladder cancer.
Hadaschik BA; ter Borg MG; Jackson J; Sowery RD; So AI; Burt HM; Gleave ME
BJU Int; 2008 Jun; 101(11):1347-55. PubMed ID: 18384637
[TBL] [Abstract][Full Text] [Related]
4. Sensitization of human bladder cancer cells to Fas-mediated cytotoxicity by cis-diamminedichloroplatinum (II).
Mizutani Y; Yoshida O; Bonavida B
J Urol; 1998 Aug; 160(2):561-70. PubMed ID: 9679929
[TBL] [Abstract][Full Text] [Related]
5. Combination treatment with trabectedin and irinotecan or topotecan has synergistic effects against ovarian clear cell carcinoma cells.
Kawano M; Mabuchi S; Kishimoto T; Hisamatsu T; Matsumoto Y; Sasano T; Takahashi R; Sawada K; Takahashi K; Takahashi T; Hamasaki T; Kimura T
Int J Gynecol Cancer; 2014 Jun; 24(5):829-37. PubMed ID: 24844217
[TBL] [Abstract][Full Text] [Related]
6. Enhancement of sensitivity of urinary bladder tumor cells to cisplatin by c-myc antisense oligonucleotide.
Mizutani Y; Fukumoto M; Bonavida B; Yoshida O
Cancer; 1994 Nov; 74(9):2546-54. PubMed ID: 7923012
[TBL] [Abstract][Full Text] [Related]
7. Concurrent platinum and docetaxel chemotherapy and external radical radiotherapy in patients with invasive transitional cell bladder carcinoma. A preliminary report of tolerance and local control.
Varveris H; Delakas D; Anezinis P; Haldeopoulos D; Mazonakis M; Damilakis J; Metaxaris G; Chondros N; Mavromanolakis E; Daskalopoulos G; Dimitrakopoulos A; Kranidis A
Anticancer Res; 1997; 17(6D):4771-80. PubMed ID: 9494605
[TBL] [Abstract][Full Text] [Related]
8. Mechanism of cisplatin resistance in human urothelial carcinoma cells.
Yu HM; Wang TC
Food Chem Toxicol; 2012 May; 50(5):1226-37. PubMed ID: 22326969
[TBL] [Abstract][Full Text] [Related]
9. Treatment with paclitaxel alone rather than combination with paclitaxel and cisplatin may be selective for cisplatin-resistant ovarian carcinoma.
Yamamoto K; Kikuchi Y; Kudoh K; Hirata J; Kita T; Nagata I
Jpn J Clin Oncol; 2000 Oct; 30(10):446-9. PubMed ID: 11185891
[TBL] [Abstract][Full Text] [Related]
10. In vitro sensitivity of human endometrial cancer cell lines to paclitaxel or irinotecan (CPT-11) in combination with other aniticancer drugs.
Hiramatsu HP; Kikuchi Y; Seto H; Nagata I
Anticancer Drugs; 2000 Aug; 11(7):573-8. PubMed ID: 11036961
[TBL] [Abstract][Full Text] [Related]
11. Synergistic antitumor effect of triptolide and cisplatin in cisplatin resistant human bladder cancer cells.
Ho JN; Byun SS; Lee S; Oh JJ; Hong SK; Lee SE; Yeon JS
J Urol; 2015 Mar; 193(3):1016-22. PubMed ID: 25229559
[TBL] [Abstract][Full Text] [Related]
12. Phase II study of paclitaxel and cisplatin for advanced urothelial cancer.
Burch PA; Richardson RL; Cha SS; Sargent DJ; Pitot HC; Kaur JS; Camoriano JK
J Urol; 2000 Nov; 164(5):1538-42. PubMed ID: 11025699
[TBL] [Abstract][Full Text] [Related]
13. Computerized quantitation of synergism and antagonism of taxol, topotecan, and cisplatin against human teratocarcinoma cell growth: a rational approach to clinical protocol design.
Chou TC; Motzer RJ; Tong Y; Bosl GJ
J Natl Cancer Inst; 1994 Oct; 86(20):1517-24. PubMed ID: 7932806
[TBL] [Abstract][Full Text] [Related]
14. Paclitaxel with cisplatin as salvage treatment for patients with previously treated advanced transitional cell carcinoma of the urothelial tract.
Uhm JE; Lim HY; Kim WS; Choi HY; Lee HM; Park BB; Park K; Kang WK
Neoplasia; 2007 Jan; 9(1):18-22. PubMed ID: 17325740
[TBL] [Abstract][Full Text] [Related]
15. Targeting urothelial carcinoma cells by combining cisplatin with a specific inhibitor of the autophagy-inducing class III PtdIns3K complex.
Schlütermann D; Skowron MA; Berleth N; Böhler P; Deitersen J; Stuhldreier F; Wallot-Hieke N; Wu W; Peter C; Hoffmann MJ; Niegisch G; Stork B
Urol Oncol; 2018 Apr; 36(4):160.e1-160.e13. PubMed ID: 29276062
[TBL] [Abstract][Full Text] [Related]
16. Protodynamic therapy for bladder cancer: in vitro results of a novel treatment concept.
Laihia JK; Pylkkänen L; Laato M; Boström PJ; Leino L
BJU Int; 2009 Nov; 104(9):1233-8. PubMed ID: 19466948
[TBL] [Abstract][Full Text] [Related]
17. Anti-cancer effects of ursane triterpenoid as a single agent and in combination with cisplatin in bladder cancer.
Lin KW; Huang AM; Lin CC; Chang CC; Hsu WC; Hour TC; Pu YS; Lin CN
Eur J Pharmacol; 2014 Oct; 740():742-51. PubMed ID: 24933647
[TBL] [Abstract][Full Text] [Related]
18. Supra-additive effect with concurrent paclitaxel and cisplatin in vulvar squamous cell carcinoma in vitro.
Raitanen M; Rantanen V; Kulmala J; Helenius H; Grénman R; Grénman S
Int J Cancer; 2002 Jul; 100(2):238-43. PubMed ID: 12115575
[TBL] [Abstract][Full Text] [Related]
19. Paclitaxel in germ cell cancer.
Motzer RJ; Chou TC; Schwartz L; Bosl GJ; Bajorin DF; Hutter H
Semin Oncol; 1995 Jun; 22(3 Suppl 6):12-5. PubMed ID: 7597428
[TBL] [Abstract][Full Text] [Related]
20. Activity- and schedule-dependent interactions of paclitaxel, etoposide and hydroperoxy-ifosfamide in cisplatin-sensitive and -refractory human ovarian carcinoma cell lines.
Klaassen U; Harstrick A; Schleucher N; Vanhoefer U; Schröder J; Wilke H; Seeber S
Br J Cancer; 1996 Jul; 74(2):224-8. PubMed ID: 8688325
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]